AbCellera publishes corporate overview on internal antibody pipeline, platform expansion strategy

• AbCellera outlined a strategy shift toward advancing an internal pipeline of antibody medicines, supported by an integrated platform spanning discovery through clinical manufacturing and development.
• The company cited 20+ internal program starts, with 2 molecules in IND-enabling activities and 2 molecules in the clinic as of March 31, 2026.
• ABCL635, an NK3R-targeting GPCR antibody for moderate-to-severe menopausal vasomotor symptoms, is in Phase 2 with a topline readout expected in Q3 2026.
• ABCL575, an OX40L program in immunology and inflammation, is in Phase 1 with a topline readout expected in Q4 2026.
• Liquidity was listed at about $655 million as of March 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abcellera Biologics Inc. published the original content used to generate this news brief on May 19, 2026, and is solely responsible for the information contained therein.